US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
PDS Biotechnology Corporation (PDSB)
PDS Biotechnology Corporation (PDSB) ニュース

PDSB

PDS Biotechnology (PDSB)

PDS Biotechnology Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PDSB

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	06 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/05/15	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/05/09	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/01/24	06 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/01/24	06 : 31	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/01/23	07 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/01/23	06 : 45	GlobeNewswire Inc.	PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer	NASDAQ:PDSB	PDS Biotechnology Corporation
2024/01/16	22 : 00	GlobeNewswire Inc.	PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/12/05	06 : 50	GlobeNewswire Inc.	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/12/05	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/11/28	21 : 30	GlobeNewswire Inc.	PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/11/28	20 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/11/14	21 : 30	GlobeNewswire Inc.	PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/11/10	06 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/11/09	22 : 00	GlobeNewswire Inc.	PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/11/07	22 : 00	GlobeNewswire Inc.	PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/24	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/23	21 : 00	GlobeNewswire Inc.	PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/12	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/11	21 : 00	GlobeNewswire Inc.	PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/04	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/04	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/03	22 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/03	20 : 00	GlobeNewswire Inc.	PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/03	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/10/02	21 : 00	GlobeNewswire Inc.	PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/09/26	21 : 00	GlobeNewswire Inc.	PDS Biotech to Present at the LD Micro Main Event XVI	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/09/25	21 : 00	GlobeNewswire Inc.	PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/09/21	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PDSB	PDS Biotechnology Corporation
2023/09/21	05 : 05	GlobeNewswire Inc.	PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference	NASDAQ:PDSB	PDS Biotechnology Corporation

Showing the most relevant articles for your search:NASDAQ:PDSB

1 2 3 4 5 6 7 8 9 10 次へ >>

Lyxor AWAT iNav

CSNAE190 Ex:18,28

SUZBOK24 - Maio 2024

NLBNPIT214N5 20991231 69...

JAC Recruitment (PK)

Tway Holdings Incorporat...

Noram Ventures (QB)

Triton Bond Trust in res...

Jackson Financia

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約